Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOXR0916 in advanced solid tumors
NCT02219724Phase 1Completed
- Sponsor
- Genentech
- Start
- Aug 2014
- Primary completion
- Jul 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of Vonlerolizumab in solid tumor (2 arms), sponsored by Genentech. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities and Percentage of Participants With Adverse Events up to 3 years. Started Aug 2014; status: completed.
02
Drugs
Vonlerolizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02219724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219724.